Summary
Prostaglandin E2 and cyclic AMP (cAMP) levels were measured in tumors and plasma of 78 patients with benign and malignant breast tumors. Two groups of malignant tissues were found, one with a high level of PGE2 M=55.4 pg/mg and one with a low level M=10.7pg/mg. The low level did not differ significantly from the benign tissue level (M=8.7 pg/mg). Two malignant groups could not be detected in the plasma levels. Plasma PGE2 concentration (in form of the 13,14-dihydro-15-Keto metabolite) did not reflect the tissue levels, and no difference was found between the benign (M=59.9 pg/ml) and the malignant (M=62.3 pg/ml) patients, but both concentrations were higher than those of healthy controls (M=34.4 pg/ml).
The stage of the cancer, the histological classification and, most important, the period of survival, could not be related to the differences in the PGE2 tissue levels. Neither could plasma cAMP be nominated as a breast cancer marker because no difference was found between the cAMP levels of benign tumor patients (M=16.48 pmol/ml), of malignant tumor patients (M=21.24 pmol/ml) and of healthy controls (M=19.07 pmol/ml). The conclusion is that although high amounts of PGE2 appear in some malignant breast tumors, they do not affect the clinical situation. These results may explain the failure to treat human breast cancer patients with prostaglandin synthetase inhibitors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- PGE2 :
-
prostaglandin E2
- cyclic AMP (cAMP):
-
cyclic adenosine 3′5′-monophosphate
- BSA:
-
bovine serum albumin
- SD:
-
standard deviation
- SE:
-
standard error
- M:
-
mean
References
Bennett A, Berstock DA, Raja B, Stamford IF (1979) Survival time after surgery is inversely related to the amounts of prostaglandins extracted from human breast cancers. Br J Pharmacol 66:451p
Bennett A, Berstock DA, Harris M, Raja B, Rowe DJF, Stamford IF, Wright JE (1980) Prostaglandins and their relationship to malignant and benign breast tumors. In: Samuelsson B, Ramwell PW, Pavletti R (eds) Advances in prostaglandin and thromboxane research. Vol 6. Raven Press, New York, pp 595–600
Bennett A, Charlier EM, McDonald AM, Simpson JS, Stamford IF, Zebro T (1977) Prostaglandins and breast cancer. Lancet II:624–626
Bennett A, Charlier EM, McDonald AM, Simpson JS, Stamford IF (1976) Bone destruction by breast tumors. Prostaglandins 11:461–462
Caro JF, Besarab A, Flynn JT (1979) Prostaglandin E and hypercalcemia in breast carcinoma — Only a tumor marker? Am J Med 66:337–341
Dowsett M, Gazet JC, Powels TJ, Easty GC, Neville AM (1976a) Benign breast lesions and osteolysis. Lancet I:970–971
Dowsett M, Easty GC, Powels TJ, Easty DM, Neville AM (1976b) Human breast tumor-induced osteolysis and prostaglandins. Prostaglandins 11:447–460
Egg D, Gantner G (1978) Effect of prostaglandins E2 on two different preparations of cyclic 3′5′-nucleotide phosphodiesterase. Pharmacol Res Commun 10:609–617
Feller N, Malachi T, Halbrecht I (1979) Prostaglandin E2 and cyclic AMP levels in human breast tumors. J Cancer Res Clin Oncol 93:275–280
Galasko CSB, Bennett A (1977) Skeletal metastases: Relationship of bone destruction, osteoclast activation and prostaglandins. Br J Cancer 35:253–254
Goldberg ML, Burke GC, Morris HP (1975) Cyclic AMP and cyclic GMP content in malignancy. Biochem Biophys Res Commun 62:320–327
Horrobin DF (1979) Cellular basis of prolactin action; Involvement of cyclic nucleotides, polyamines, prostaglandins, steroids, thyroid hormones, Na/K ATPases and calcium; Relevance to breast cancer and the menstrual cycle. Med Hypothesis 5:599–620
Karmali RA (1980) Prostaglandins and cancer. Prostaglandins Med 5:11–28
Kibbey WE, Bronn DG, Minton JP (1979) Prostaglandin synthetase and Prostaglandin E2 levels in human breast carcinoma. Prostaglandins Med 2:133–139
Klein DC, Raisz LG (1970) Prostaglandins-Stimulation of bone resorption in tissue culture. Endocrinology 86:1436–1440
Küng W, Bechtel E, Geyer E, Salokangas A, Preisz J, Huber P, Torhorst J, Jungmann RA, Kalmadge K, Eppenberger U (1977) Altered levels of cyclic nucleotides, cyclic AMP phosphodiesterase and adenyl cyclase activities in normal, dysplastic and neoplastic human mammary tissue. FEBS Lett 82:102–106
Leaper DJ, French BT, Bennett A (1979) Breast cancer and prostaglandins, a new approach to treatment. Br J Surg 66:683–686
Little CL, McSweeney JR, Millar NJ, O'Moore RR, Weir DG (1979) Cyclic AMP — a tumor marker? Ir J Med Sci 148:112–113
Martin PM, Jacquemier J, Rolland AM, Toga M (1980) Prostaglandin production and metabolism in human breast cancer. In: Samuelsson B, Ramwell PW, Pavletti R (eds) Advances in prostaglandin and thromboxane research, Vol 6. Raven Press, New York, pp 575–581
Minton JP (1974) Elevated cyclic AMP levels in human breast cancer. J Natl Cancer Inst 53:283–284
Minton JP, Mattews RH, Weisenbaugh TW (1976) Elevated adenosine 3′5′-cyclic monosphosphate levels in human and animals tumors in vivo. J Natl Cancer Inst 47:39–41
Powles TJ, Dady PJ, Williams J, Easty GC, Coombes RC (1980) Use of inhibitors of prostaglandin synthesis in patients with breast cancer. In: Samuelsson B, Ramwell PW, Pavletti R (eds) Advances in prostaglandin and thromboxane research, Vol 6. Raven Press, New York, pp 511–517
Powles TJ, Coombes RC, Neville AM, Ford HT, Gazet JC (1977) 15-Keto-13, 14-dihydroprostaglandin E2 concentrations in serum of patients with breast cancer. Lancet II:138
Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M (1980) Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 64:1061–1071
Sanders RR, Lee WH, Koh L, Jones WR (1980) Plasma prostaglandin Flevels and malignant tumors of the female genital tract. Br J Obstet Gynaecol 87:139–142
Stamfort IF, MacIntyre J, Bennett A, Rolland PH (1980) Human breast carcinomas release prostaglandin-like material into the blood. In: Samuelsson B, Pavletti R (eds) Advances in prostaglandin and thromboxane research, Vol 6. Raven Press, New York, pp 571–575
Stevens RH, Loven DP, Osborne JW, Prall JL (1978) Cyclic nucleotide concentrations and X-ray-in-duced rat small intestinal cancer. Cancer Lett 4:325–332
Yu JH, Wells H, Ryan WJ Jr, Lloyd WS (1976) Effects of prostaglandins and other drugs on the cyclic AMP content of cultured bone cells. Prostaglandins 12:501–513
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Malachi, T., Chaimoff, C., Feller, N. et al. Prostaglandin E2 and cyclic AMP in tumor and plasma of breast cancer patients. J Cancer Res Clin Oncol 102, 71–79 (1981). https://doi.org/10.1007/BF00410536
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00410536